[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112021025462A2 - Methods for producing a bispecific bivalent antibody and a recombinant mammalian cell, deoxyribonucleic acid, use of a deoxyribonucleic acid, recombinant mammalian cell and composition - Google Patents

Methods for producing a bispecific bivalent antibody and a recombinant mammalian cell, deoxyribonucleic acid, use of a deoxyribonucleic acid, recombinant mammalian cell and composition

Info

Publication number
BR112021025462A2
BR112021025462A2 BR112021025462A BR112021025462A BR112021025462A2 BR 112021025462 A2 BR112021025462 A2 BR 112021025462A2 BR 112021025462 A BR112021025462 A BR 112021025462A BR 112021025462 A BR112021025462 A BR 112021025462A BR 112021025462 A2 BR112021025462 A2 BR 112021025462A2
Authority
BR
Brazil
Prior art keywords
domain
mammalian cell
deoxyribonucleic acid
heavy chain
light chain
Prior art date
Application number
BR112021025462A
Other languages
Portuguese (pt)
Inventor
Christina-Lisa Hoeck
Johannes Auer
Monika Popp
Simon Auslaender
Ulrich Goepfert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112021025462A2 publication Critical patent/BR112021025462A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição. no presente documento é relatado um método para produzir um anticorpo bivalente biespecífico, compreendendo as etapas de cultivar uma célula de mamífero compreendendo um ácido desoxirribonucleico que codifica o anticorpo bivalente biespecífico, e recuperar o anticorpo bivalente biespecífico da célula ou do meio de cultivo, em que o ácido desoxirribonucleico que codifica o anticorpo bivalente biespecífico é integrado de forma estável no genoma da célula de mamífero e compreende na direção 5' para 3' um primeiro cassete de expressão que codifica a primeira cadeia leve, um segundo cassete de expressão que codifica a primeira cadeia pesada, um terceiro cassete de expressão que codifica a segunda cadeia leve, e um quarto cassete de expressão que codifica a segunda cadeia pesada, ou um primeiro cassete de expressão que codifica a primeira cadeia leve, um segundo cassete de expressão que codifica a segunda cadeia pesada, um terceiro cassete de expressão que condifica a segunda cadeia leve, e um quarto cassete de expressão que codifica a primeira cadeia pesada, em que a primeira cadeia pesada compreende do terminal n ao c um primeiro domínio variável de cadeia pesada, um domínio ch1, uma região de dobradiça, um domínio ch2 e um domínio ch3, a segunda cadeia pesada compreende do terminal n ao c o primeiro domínio variável de cadeia leve, um domínio ch1, uma região de dobradiça, um domínio ch2 e um domínio ch3, a primeira cadeia leve compreende do terminal n ao c, um segundo domínio variável de cadeia pesada e um domínio cl, e a segunda cadeia leve compreende do terminal n ao c, um segundo domínio variável de cadeia leve e um domínio cl, em que o primeiro domínio variável de cadeia pesada e o segundo domínio variável de cadeia leve formam um primeiro local de ligação e o segundo domínio variável de cadeia pesada e o primeiro domínio variável de cadeia leve formam um segundo local de ligação.methods for producing a bispecific bivalent antibody and a recombinant mammalian cell, deoxyribonucleic acid, use of a deoxyribonucleic acid, recombinant mammalian cell and composition. reported herein is a method for producing a bispecific bivalent antibody, comprising the steps of culturing a mammalian cell comprising a deoxyribonucleic acid encoding the bispecific bivalent antibody, and recovering the bispecific bivalent antibody from the cell or culture medium, wherein the deoxyribonucleic acid encoding the bispecific bivalent antibody is stably integrated into the genome of the mammalian cell and comprises in the 5' to 3' direction a first expression cassette encoding the first light chain, a second expression cassette encoding the first heavy chain, a third expression cassette encoding the second light chain, and a fourth expression cassette encoding the second heavy chain, or a first expression cassette encoding the first light chain, a second expression cassette encoding the second heavy chain, a third expression cassette that encodes the second light chain, and a fourth expression cassette encoding the first heavy chain, wherein the first heavy chain comprises from the n to c terminus a first heavy chain variable domain, a ch1 domain, a hinge region, a ch2 domain and a ch3 domain, the second heavy chain comprises from the n-terminus to the co-terminus of the light chain, a ch1 domain, a hinge region, a ch2 domain and a ch3 domain, the first light chain comprises, from the n-terminus to the c, a second chain variable domain heavy chain and a cl domain, and the second light chain comprises, from the n to the c terminus, a second light chain variable domain and a cl domain, wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site and the second heavy chain variable domain and the first light chain variable domain form a second binding site.

BR112021025462A 2019-06-19 2020-06-17 Methods for producing a bispecific bivalent antibody and a recombinant mammalian cell, deoxyribonucleic acid, use of a deoxyribonucleic acid, recombinant mammalian cell and composition BR112021025462A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181097 2019-06-19
PCT/EP2020/066685 WO2020254355A1 (en) 2019-06-19 2020-06-17 Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization

Publications (1)

Publication Number Publication Date
BR112021025462A2 true BR112021025462A2 (en) 2022-02-01

Family

ID=67060257

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025462A BR112021025462A2 (en) 2019-06-19 2020-06-17 Methods for producing a bispecific bivalent antibody and a recombinant mammalian cell, deoxyribonucleic acid, use of a deoxyribonucleic acid, recombinant mammalian cell and composition

Country Status (11)

Country Link
US (1) US20220169730A1 (en)
EP (1) EP3986926A1 (en)
JP (2) JP2022537338A (en)
KR (1) KR20220010019A (en)
CN (1) CN114008081A (en)
AU (1) AU2020294879A1 (en)
BR (1) BR112021025462A2 (en)
CA (1) CA3140318A1 (en)
IL (1) IL288967A (en)
MX (1) MX2021015538A (en)
WO (1) WO2020254355A1 (en)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
HUP0300369A2 (en) 2000-04-11 2003-06-28 Genentech, Inc. Multivalent antibodies and uses therefor
WO2006007850A1 (en) 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
MX350962B (en) 2008-01-07 2017-09-27 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects.
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
MX2011010159A (en) 2009-04-02 2011-10-17 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments.
PT2417156E (en) * 2009-04-07 2015-04-29 Roche Glycart Ag Trivalent, bispecific antibodies
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
HUE061692T2 (en) 2011-05-27 2023-08-28 Hoffmann La Roche Dual targeting
WO2013006142A1 (en) 2011-07-05 2013-01-10 Nanyang Technological University A novel process and reagent for rapid genetic alterations in eukaryotic cells
LT2872534T (en) 2012-07-13 2018-10-25 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
KR102431342B1 (en) 2015-10-02 2022-08-10 에프. 호프만-라 로슈 아게 Bispecific antibodies specific for pd1 and tim3
CN109071633B (en) 2016-04-20 2022-11-18 瑞泽恩制药公司 Compositions and methods based on the use of expression enhancing loci for the production of antibodies
NZ756132A (en) 2017-03-10 2022-02-25 Hoffmann La Roche Method for producing multispecific antibodies
JP6997212B2 (en) * 2017-04-05 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibodies that specifically bind to PD1 and LAG3

Also Published As

Publication number Publication date
MX2021015538A (en) 2022-02-10
JP2022537338A (en) 2022-08-25
KR20220010019A (en) 2022-01-25
CN114008081A (en) 2022-02-01
CA3140318A1 (en) 2020-12-24
JP2024059798A (en) 2024-05-01
US20220169730A1 (en) 2022-06-02
AU2020294879A1 (en) 2021-12-16
EP3986926A1 (en) 2022-04-27
WO2020254355A1 (en) 2020-12-24
IL288967A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
CL2008002349A1 (en) Human cd37-binding antibody molecule; DNA molecule that encodes it; expression vector and host cell; method of producing said antibody; pharmaceutical composition comprising it; In vitro method of suppressing cd37-expressing b cells in a population of cells.
AR080942A1 (en) HETEROMULTIMERIC PROTEIN PRODUCTION
BR112013009275A2 (en) anti-folate receptor alpha antibody glycoforms
NZ614857A (en) Bispecific antibodies and methods for production thereof
AR069956A1 (en) PROCESSES TO CULTIVATE MAMPHERE CELLS SECRETORS OF HETEROLOGICAL BLOOD PROTEINS
BRPI0812091A2 (en) METHOD FOR MANUFACTURING A RECOMBINANT POLYCLONAL PROTEIN
BR112015022971A2 (en) Manufacturing methods for controlling the content of c-terminal lysine, galactose and sialic acid in recombinant proteins
EA201290068A1 (en) METHODS AND COMPOSITIONS FOR IMPROVING THE TRANSPORT OF SUGARS, CONSTRUCTION OF MIXED SUGARS AND PRODUCTION OF BIOFUELS
ES2570382T3 (en) Compositions and methods for the production of fermentable sugars
TW200745164A (en) Gene recombination antibodies composition
BRPI0821777B8 (en) bivalent bispecific antibody, method of preparation thereof and composition
RU2013133846A (en) ANTIBODIES AGAINST IL-18 AND THEIR APPLICATION
SG196836A1 (en) Cancer stem cell population and method for production thereof
BR112013002695A2 (en) mice producing binding proteins comprising v1 domains.
WO2010125187A3 (en) Method for the production of domain antibodies
CL2009002004A1 (en) Antibody or fragment thereof that binds to interleukin 4 receptor comprising a light and heavy chain variable region; nucleic acid sequences encoding said regions; vector comprising said sequence; host cell; method for producing said antibody; and use of said antibody for immunological disorders.
BR112018075688A2 (en) anti-c5 antibodies and methods of use
BR112015019343A2 (en) ANTI-HER2 ANTIBODY, COMPOSITION, METHOD FOR PRODUCING A POPULATION OF ANTIBODIES, MAMMARY GLAND EPITHELIAL CELLS, AND, TRANSGENIC NON-HUMAN MAMMAL
PA8770701A1 (en) CONCRETE COMPOSITIONS WITH HIGH FUNCTIONALITY AND WITH MINIMUM OF EXUDATION AND SEGREGATION
BR112018009067A2 (en) anti-c5 antibodies and methods of use
CR20240181A (en) Cd19 binding molecules and uses thereof
RU2017127208A (en) STRUCTURE OF THE EXPRESSION VECTOR, NEW METHODS FOR PRODUCING CELL PRODUCERS AND THEIR APPLICATION FOR RECOMBINANT PRODUCTION OF POLYEPEPTIDES
WO2012143645A3 (en) Cosmetic composition including a cucurbic acid compound and a mixture of sulfonic and acrylic polymers
BR112015005604A2 (en) expression vectors comprising chimeric cytomegalovirus enhancer and promoter sequences
TW200728229A (en) Optical glass for pressure forming